Cellectis S.A. (CLLS)

NGM – Real vaqt narxi. Valyuta: USD

3.96

+0.11 (2.86%)

Yopilishda: May 12, 2026, 4:00 PM EDT

3.96

0.00 (0.00%)

Bozor oldidan: May 13, 2026, 8:07 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Cellectis S.A. (CLLS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cellectis S.A. (CLLS)

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

Cellectis Reports Financial Results for the First Quarter 2026

Monthly information on share capital and company voting rights

Cellectis to Report First Quarter Financial Results on May 11, 2026

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform

Monthly information on share capital and company voting rights

Videolar

No Data

Press-relizlar

Cellectis Reports Financial Results for the First Quarter 2026

Monthly information on share capital and company voting rights

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform

Search stocks

Cellectis S.A. (CLLS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cellectis S.A. (CLLS)

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

Cellectis Reports Financial Results for the First Quarter 2026

Monthly information on share capital and company voting rights

Cellectis to Report First Quarter Financial Results on May 11, 2026

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform

Monthly information on share capital and company voting rights

Videolar

No Data

Press-relizlar

Cellectis Reports Financial Results for the First Quarter 2026

Monthly information on share capital and company voting rights

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform